Diamyd Medical AB

Equities

DMYD B

SE0005162880

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:51:53 23/05/2024 pm IST			5-day change	1st Jan Change
11.76 ^SEK	-1.18%		-1.67%	+79.00%

16/05	Diamyd Medical AB Updates on the Registrational Phase 3 Trial	CI
18/04	Diamyd Medical Raises SEK57 Million in Rights Issue	MT

Diamyd Medical Announces Executive Changes

February 02, 2015 at 12:59 pm IST

Diamyd Medical informed that President and CEO Peter Zerhouni will move on to a position as CEO with another company active in drug development. The company's
Chairman will take over as Acting President and CEO from March 1, 2015. While Anders Essen-Möller is Acting President and CEO, the Board Member lawyer Erik Nerpin will assume the role of Chairman of the Board.

Latest news about Diamyd Medical AB

Diamyd Medical AB Updates on the Registrational Phase 3 Trial	16/05	CI
Diamyd Medical Raises SEK57 Million in Rights Issue	18/04	MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	12/04	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	27/03	CI
Diamyd Medical to Raise SEK114 Million Via Share Offering	19/03	MT
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	29/02	CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment	15/02	MT
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	24/01	CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023	24/01	CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024	04/01	CI
Certain B Shares of Diamyd Medical AB are subject to a Lock-Up Agreement Ending on 27-DEC-2023.	27/12	CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea	06/12	CI
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board	30/11	CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial	07/11	MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial	07/11	CI
Diamyd Medical Raises SEK78 Million from Partially Subscribed Rights Issue	02/11	MT
Diamyd Medical to Raise SEK78 Million from Partially Subscribed Rights Issue; Stock Jumps	01/11	MT
Diamyd Medical Reports Updated Data on Subcutaneous Treatment to Delay Type 1 Diabetes Onset in Kids	26/23/26	MT
Diamyd Medical AB Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset	26/23/26	CI
Transcript : Diamyd Medical AB - Special Call	20/23/20
Diamyd Medical’s Diabetes Drug Shows Booster Safety in Mid-stage Study; Shares Jump	20/23/20	MT
Diamyd Medical AB Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection	20/23/20	CI
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	11/23/11	CI
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2023	11/23/11	CI
Diamyd Medical Founder Joins as Chairman	02/23/02	MT

Chart Diamyd Medical AB

Duration

Period

More charts

Company Profile

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Sector

Biotechnology & Medical Research

Calendar

26/06/2024 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Diamyd Medical AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMYD MEDICAL AB	+79.00%	111M
VERTEX PHARMACEUTICALS INCORPORATED	+10.50%	115B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-4.37%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.28%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.05%	14.03B
SAREPTA THERAPEUTICS, INC.	+30.93%	12.13B

Bio Therapeutic Drugs